The only dual ingredient injectable corticosteroid
approved by the FDA for use in horses
The link between
RAPID ONSET and LONG-ACTING RELIEF
of pain and inflammation1


1. Trotter GW. Intra-articular corticosteroids. In: Mcllwraith CW, Trotter GW, eds. Joint Disease in the Horse. Philadelphia, PA; W.B. Saunders, 1996;237-256.

BETAVET®(Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension) For Intra-Articular (I.A.) Use in Horses. CAUTION:Federal law restricts this drug to use by or on the order of a licensed veterinarian. INDICATION
For the control of pain and inflammation associated with osteoarthritis in horses.
IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS
BETAVET® is contraindicated in horses with hypersensitivity to betamethasone. Intra-articular injection of corticosteroids for local effect is contraindicated in the presence of septic arthritis.
WARNINGS: Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. HUMAN WARNINGS: Not for use in humans. For use in animals only. Keep this and all medications out of the reach of children. Consult a physician in the case of accidental human exposure. PRECAUTIONS: Corticosteroids, including BETAVET®, administered intra-articularly are systemically absorbed. Do not use in horses with acute infections. Acute moderate to severe exacerbation of pain, further loss of joint motion, fever, or malaise within several days following intra-articular injection may indicate a septic process. Because of the anti-inflammatory action of corticosteroids, signs of infection in the treated joint may be masked.

Due to the potential for exacerbation of clinical signs of laminitis, glucocorticoids should be used with caution in horses with a history of laminitis, or horses otherwise at a higher risk for laminitis. Use with caution in horses with chronic nephritis, equine pituitary pars intermedia dysfunction (PPID), and congestive heart failure. Concurrent use of other anti-inflammatory drugs, such as NSAIDs or other corticosteroids, should be approached with caution. Due to the potential for systemic exposure, concomitant use of NSAIDs and corticosteroids may increase the risk of gastrointestinal, renal, and other toxicity. Consider appropriate wash out times prior to administering additional NSAIDs or corticosteroids.
ADVERSE REACTIONS: Adverse reactions reported with BETAVET® during a field study of 239 horses of various breeds which had been administered either BETAVET® (n=119 ) or a saline control (n=120 ) at five percent (5 %) and above were: acute joint effusion and /or local injection site swelling (within 2 days of injection ), increased lameness (within the first 5 days ), loose stool and depression. DOSAGE AND ADMINISTRATION: Shake well immediately before use. BETAVET® should be administered with strict aseptic technique. BETAVET® may be administered concurrently in up to 2 joints per horse. Use immediately after opening and discard remaining contents.
About BetaVet®
FDA Approved for the control of pain and
inflammation associated with equine osteoarthritis
Two Active Ingredients
  • Betamethasone sodium phosphate - 3.15 mg2; a highly soluble betamethasone ester with a rapid onset of action1
  • Betamethasone acetate - 2.85 mg2; a less soluble betamethasone ester with a prolonged action1
  • Time to peak plasma concentations (Tmax) achieved in as little as 4.5 to 8 hours
    - Clinical significance of these results is unknown


1. Trotter GW. Intra-articular corticosteroids. In: Mcllwraith CW, Trotter GW, eds. Joint Disease in the Horse. Philadelphia, PA; W.B. Saunders, 1996;237-256.
2. Freedom of Information Summary, BetaVet NADA 141-418.

Selected Safety Information
BETAVET®(Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension) For Intra-Articular (I.A.) Use in Horses. CAUTION:Federal law restricts this drug to use by or on the order of a licensed veterinarian. INDICATION
For the control of pain and inflammation associated with osteoarthritis in horses.
IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS
BETAVET® is contraindicated in horses with hypersensitivity to betamethasone. Intra-articular injection of corticosteroids for local effect is contraindicated in the presence of septic arthritis.
WARNINGS: Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. HUMAN WARNINGS: Not for use in humans. For use in animals only. Keep this and all medications out of the reach of children. Consult a physician in the case of accidental human exposure. PRECAUTIONS: Corticosteroids, including BETAVET®, administered intra-articularly are systemically absorbed. Do not use in horses with acute infections. Acute moderate to severe exacerbation of pain, further loss of joint motion, fever, or malaise within several days following intra-articular injection may indicate a septic process. Because of the anti-inflammatory action of corticosteroids, signs of infection in the treated joint may be masked.

Due to the potential for exacerbation of clinical signs of laminitis, glucocorticoids should be used with caution in horses with a history of laminitis, or horses otherwise at a higher risk for laminitis. Use with caution in horses with chronic nephritis, equine pituitary pars intermedia dysfunction (PPID), and congestive heart failure. Concurrent use of other anti-inflammatory drugs, such as NSAIDs or other corticosteroids, should be approached with caution. Due to the potential for systemic exposure, concomitant use of NSAIDs and corticosteroids may increase the risk of gastrointestinal, renal, and other toxicity. Consider appropriate wash out times prior to administering additional NSAIDs or corticosteroids.
ADVERSE REACTIONS: Adverse reactions reported with BETAVET® during a field study of 239 horses of various breeds which had been administered either BETAVET® (n=119 ) or a saline control (n=120 ) at five percent (5 %) and above were: acute joint effusion and /or local injection site swelling (within 2 days of injection ), increased lameness (within the first 5 days ), loose stool and depression. DOSAGE AND ADMINISTRATION: Shake well immediately before use. BETAVET® should be administered with strict aseptic technique. BETAVET® may be administered concurrently in up to 2 joints per horse. Use immediately after opening and discard remaining contents.
Dosing and
Administration
Dosing & Administration
  • Shake well immediately before use
  • Using strict aseptic technique, administer 1.5 mL Betavet® (9 mg total betamethasone) per joint by intra-articular injection (IA)
  • Betavet® may be administered concurrently in up to 2 joints per horse
  • Use immediately after opening; then discard any remaining contents
Advantages of Betavet® over Compounded Injectable Corticosteroids3

  • FDA approved for use in horses
  • Safety and efficacy backed by clinical studies
  • Consistency in product quality and potency
  • Product stability proven to ensure consistent safety and efficacy over the entire shelf life


3. BetaVet (Package Insert) Shirley, NY: Luitpold Animal Health, Division of Luitpold Pharmaceuticals, Inc., 2014
Selected Safety Information
BETAVET®(Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension) For Intra-Articular (I.A.) Use in Horses. CAUTION:Federal law restricts this drug to use by or on the order of a licensed veterinarian. INDICATION
For the control of pain and inflammation associated with osteoarthritis in horses.
IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS
BETAVET® is contraindicated in horses with hypersensitivity to betamethasone. Intra-articular injection of corticosteroids for local effect is contraindicated in the presence of septic arthritis.
WARNINGS: Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. HUMAN WARNINGS: Not for use in humans. For use in animals only. Keep this and all medications out of the reach of children. Consult a physician in the case of accidental human exposure. PRECAUTIONS: Corticosteroids, including BETAVET®, administered intra-articularly are systemically absorbed. Do not use in horses with acute infections. Acute moderate to severe exacerbation of pain, further loss of joint motion, fever, or malaise within several days following intra-articular injection may indicate a septic process. Because of the anti-inflammatory action of corticosteroids, signs of infection in the treated joint may be masked.

Due to the potential for exacerbation of clinical signs of laminitis, glucocorticoids should be used with caution in horses with a history of laminitis, or horses otherwise at a higher risk for laminitis. Use with caution in horses with chronic nephritis, equine pituitary pars intermedia dysfunction (PPID), and congestive heart failure. Concurrent use of other anti-inflammatory drugs, such as NSAIDs or other corticosteroids, should be approached with caution. Due to the potential for systemic exposure, concomitant use of NSAIDs and corticosteroids may increase the risk of gastrointestinal, renal, and other toxicity. Consider appropriate wash out times prior to administering additional NSAIDs or corticosteroids.
ADVERSE REACTIONS: Adverse reactions reported with BETAVET® during a field study of 239 horses of various breeds which had been administered either BETAVET® (n=119 ) or a saline control (n=120 ) at five percent (5 %) and above were: acute joint effusion and /or local injection site swelling (within 2 days of injection ), increased lameness (within the first 5 days ), loose stool and depression. DOSAGE AND ADMINISTRATION: Shake well immediately before use. BETAVET® should be administered with strict aseptic technique. BETAVET® may be administered concurrently in up to 2 joints per horse. Use immediately after opening and discard remaining contents.
Efficacy Data
Pivotal Field Efficacy Study for BetaVet®2
  • Field efficacy study consisted of a negative control, randomized, masked field trial among 239 horses
    • Final effectiveness analysis N=229
      • BetaVet® n=114
      • Saline (Control) n=115
    • Clinical success was defined as: improvement in one lameness grade according to the AAEP lameness scoring system on Day 5 following treatment
  • Success rate for horses in the BetaVet® group was statistically significantly different (p=0.0061) than that in the Saline group
    • BetaVet® clinical success rate 75.73% (n=87)
      • BetaVet® failure rate n=27
    • Saline (Control) clinical success rate of 52.52% (n=61)
      • Saline failure rate n=54

BetaVet® Target Animal Safety Study2

  • N=32 horses of various breeds and ages
  • Ages 2-18 years, 16 geldings/16 mares
  • Weighing 827-1219 lbs.
A 3-week target animal safety (TAS) study was conducted to evaluate the safety of BetaVet® in mature, healthy horses.
  • 4 treatment groups, n=8 horses per group
  • BetaVet® was administered as an IA injection (left middle carpal joint) at (0X)* 0, (1X) 0.0225, (2X) 0.045, and (4X) 0.09 mg/lb, for three treatments, five days apart
*Control horses (0X) were administered Saline at a volume equivalent to the 4X group.
  • Measurements and Observations — Daily observations, adverse events, physical examinations, injection site observations, body weights, and clinical pathology. Gross necropsy and histopathology were performed post-mortem
  • Results — Injection site reactions were the most common observations in all treatment groups, with the 4X BetaVet® group having the highest overall incidence and severity of injection site reactions
Conclusions — Treatment with BetaVet® was associated with dose dependent injection site abnormalities (swelling, pain, and lameness.) This study supported the FDA approval of BetaVet® when administered IA to horses in a maximum of 2 joints at a one-time dose of 9 mg per joint.


2. Freedom of Information Summary, BetaVet NADA 141-418.

Selected Safety Information
BETAVET®(Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension) For Intra-Articular (I.A.) Use in Horses. CAUTION:Federal law restricts this drug to use by or on the order of a licensed veterinarian. INDICATION
For the control of pain and inflammation associated with osteoarthritis in horses.
IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS
BETAVET® is contraindicated in horses with hypersensitivity to betamethasone. Intra-articular injection of corticosteroids for local effect is contraindicated in the presence of septic arthritis.
WARNINGS: Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. HUMAN WARNINGS: Not for use in humans. For use in animals only. Keep this and all medications out of the reach of children. Consult a physician in the case of accidental human exposure. PRECAUTIONS: Corticosteroids, including BETAVET®, administered intra-articularly are systemically absorbed. Do not use in horses with acute infections. Acute moderate to severe exacerbation of pain, further loss of joint motion, fever, or malaise within several days following intra-articular injection may indicate a septic process. Because of the anti-inflammatory action of corticosteroids, signs of infection in the treated joint may be masked.

Due to the potential for exacerbation of clinical signs of laminitis, glucocorticoids should be used with caution in horses with a history of laminitis, or horses otherwise at a higher risk for laminitis. Use with caution in horses with chronic nephritis, equine pituitary pars intermedia dysfunction (PPID), and congestive heart failure. Concurrent use of other anti-inflammatory drugs, such as NSAIDs or other corticosteroids, should be approached with caution. Due to the potential for systemic exposure, concomitant use of NSAIDs and corticosteroids may increase the risk of gastrointestinal, renal, and other toxicity. Consider appropriate wash out times prior to administering additional NSAIDs or corticosteroids.
ADVERSE REACTIONS: Adverse reactions reported with BETAVET® during a field study of 239 horses of various breeds which had been administered either BETAVET® (n=119 ) or a saline control (n=120 ) at five percent (5 %) and above were: acute joint effusion and /or local injection site swelling (within 2 days of injection ), increased lameness (within the first 5 days ), loose stool and depression. DOSAGE AND ADMINISTRATION: Shake well immediately before use. BETAVET® should be administered with strict aseptic technique. BETAVET® may be administered concurrently in up to 2 joints per horse. Use immediately after opening and discard remaining contents.
Safety Data
Adverse Reactions from BetaVet® Pivotal Field Efficacy Study3

  • The most common adverse reactions included local swelling, mild increases in lameness, loose stool, increased heat in the treated joint, depression, anxiety and inappetance

Comparison of adverse reactions of BetaVet® (n=119) treated vs. Saline (Control) (n=120) group horses
3. BetaVet (Package Insert) Shirley, NY: Luitpold Animal Health, Division of Luitpold Pharmaceuticals, Inc., 2014

Selected Safety Information
BETAVET®(Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension) For Intra-Articular (I.A.) Use in Horses. CAUTION:Federal law restricts this drug to use by or on the order of a licensed veterinarian. INDICATION
For the control of pain and inflammation associated with osteoarthritis in horses.
IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS
BETAVET® is contraindicated in horses with hypersensitivity to betamethasone. Intra-articular injection of corticosteroids for local effect is contraindicated in the presence of septic arthritis.
WARNINGS: Do not use in horses intended for human consumption. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. HUMAN WARNINGS: Not for use in humans. For use in animals only. Keep this and all medications out of the reach of children. Consult a physician in the case of accidental human exposure. PRECAUTIONS: Corticosteroids, including BETAVET®, administered intra-articularly are systemically absorbed. Do not use in horses with acute infections. Acute moderate to severe exacerbation of pain, further loss of joint motion, fever, or malaise within several days following intra-articular injection may indicate a septic process. Because of the anti-inflammatory action of corticosteroids, signs of infection in the treated joint may be masked.

Due to the potential for exacerbation of clinical signs of laminitis, glucocorticoids should be used with caution in horses with a history of laminitis, or horses otherwise at a higher risk for laminitis. Use with caution in horses with chronic nephritis, equine pituitary pars intermedia dysfunction (PPID), and congestive heart failure. Concurrent use of other anti-inflammatory drugs, such as NSAIDs or other corticosteroids, should be approached with caution. Due to the potential for systemic exposure, concomitant use of NSAIDs and corticosteroids may increase the risk of gastrointestinal, renal, and other toxicity. Consider appropriate wash out times prior to administering additional NSAIDs or corticosteroids.
ADVERSE REACTIONS: Adverse reactions reported with BETAVET® during a field study of 239 horses of various breeds which had been administered either BETAVET® (n=119 ) or a saline control (n=120 ) at five percent (5 %) and above were: acute joint effusion and /or local injection site swelling (within 2 days of injection ), increased lameness (within the first 5 days ), loose stool and depression. DOSAGE AND ADMINISTRATION: Shake well immediately before use. BETAVET® should be administered with strict aseptic technique. BETAVET® may be administered concurrently in up to 2 joints per horse. Use immediately after opening and discard remaining contents.
Resources
BetaVet® Facts Brochure



BetaVet® Technical Bulletin



FDA Approved vs. Compounded Products Technical Bulletin



Laminitis Technical Bulletin











Contact
Customer Service: To place an order, check order status, inquire about pricing or process a return By Phone:
(800) 458-0163
(8:30 AM - 6:00 PM Monday - Thursday and Friday 8:30 AM - 5:00 PM eastern time)

By Mail:
One Luitpold Drive
P.O. Box 9001
Shirley, NY 11967



By Fax:
(866) 597-1991



By Email:
cs@luitpold.com



Contact Sales Representative:
click here


Report an Adverse Drug Reaction: To report an adverse event for any Luitpold Animal Health product
  • Contact Luitpold Animal Health
  • Contact the Center for Veterinary Medicine
    • Submit a form at this link
    • Call the Center for Veterinary Medicine: (888) FDA-VETS
Report a Product Quality Complaint: To report a product quality complaint for any Luitpold Animal Health product
  • Contact Luitpold Animal Health
Medical Information Form: For medical or technical questions about Luitpold Animal Health Products, please complete the form at this link.




Online ordering system for veterinarians Purchase BetaVet® Online Now! Or Call Customer Service Today!
(800) 458-0163
Online ordering system for veterinarians Purchase BetaVet® Online Now!

Or Call Customer Service Today! (800) 458-0163


Copyright © 2016 Luitpold Pharmaceuticals, Inc. All rights reserved.
BetaVet® and the Horse Head design are registered trademarks of Luitpold Pharmaceuticals, Inc.
©Luitpold Animal Health, division of Luitpold Pharmaceuticals, Inc. 2017. Luitpold Animal Health website, PP-BV-US-0002      5/2017